
Microba and Genetic Signatures merger will not proceed
Key points
- Genetic Signatures has decided not to go ahead with its proposed merger with Microba Life Sciences.
- Microba shares remain in voluntary suspension, last trading at $0.036.
- Microba said it is assessing its cash flow and exploring funding options while suspended.
Microba Life Sciences (ASX:MAP) said its proposed merger with Genetic Signatures (ASX:GSS) will not proceed, after Genetic Signatures resolved not to go ahead.
Genetic Signatures made the decision after Microba said it would not have the financial capacity to complete the merger without more capital.
Microba said it needed extra capital because the second tranche of its institutional placement, announced on 20 October 2026, could not proceed.
Changes to the merger’s indicative terms meant Microba could not meet the placement’s conditions, although its board considered the revised terms generally commercially acceptable.
Microba said it is continuing to assess its cash flow and explore funding options while it remains in voluntary suspension. Following the announcement the Microba shares remained in suspension, last trading at $0.036.
Microba requested a voluntary suspension of trading on 17 November 2026 while it explores funding options.
Microba develops clinical-grade microbiome tests, and said the end of the merger follows many months of discussions and due diligence.

